Picture of SIGA Technologies logo

SIGA — SIGA Technologies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapFalling Star

SIGA Technologies Q3 net loss narrows on international sales

SIGA Technologies Q3 net loss narrows on international sales


Overview

  • U.S. pharmaceutical firm's Q3 revenue and product sales declined year-over-year

  • Company posted Q3 net loss, narrowing from year-ago period

  • Awarded $15 mln oral TPOXX contract from Canadian Department of National Defence in October


Outlook

  • Company is actively pursuing new international government contracts to diversify its customer base

  • SIGA continues to seek a new TPOXX procurement contract with the U.S. Government

  • Canadian Department of National Defence contract includes firm commitments of about $9 mln over three years


Result Drivers

  • INTERNATIONAL SALES - Co delivered $13 mln of oral TPOXX to two international customers in first nine months

  • U.S. CONTRACT FULFILLMENT - Co completed final IV TPOXX deliveries to U.S. Strategic National Stockpile under 19C contract


Company press release: ID:nGNX6ctWPp


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$2.9 mln


Analyst Coverage

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago


Reuters Recommended Reads

  • Nov 9 - Tonix Pharmaceuticals Q3 revenue jumps on TONMYA sales

  • Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on SIGA Technologies

See all news